Case Volume Affects Mortality for Immunosuppressed With Sepsis

Share this content:
Case Volume Affects Mortality for Immunosuppressed With Sepsis
Case Volume Affects Mortality for Immunosuppressed With Sepsis

FRIDAY, June 8, 2018 (HealthDay News) -- At hospitals with the lowest volume of immunosuppressed patients with sepsis, the risk of death from sepsis due to a suppressed immune state is highest, according to a study published online June 1 in the Annals of the American Thoracic Society.

Jared A. Greenberg, M.D., from the Rush University Medical Center in Chicago, and colleagues characterized patients with sepsis at hospitals according to immune state. Variation in the odds of in-hospital death from sepsis due to a suppressed immune state was examined based on the average volume of immunosuppressed patients with sepsis each year.

The researchers identified 350,183 patients with sepsis at 60 hospitals from 2010 to 2012. Compared with non-immunosuppressed patients with sepsis, immunosuppressed patients with sepsis at the 15 hospitals in the first quartile had increased odds of in-hospital death (adjusted odds ratio, 1.38). For patients at hospitals in the second, third, and fourth quartiles, the odds of in-hospital death for immunosuppressed patients with sepsis relative to non-immunosuppressed patients with sepsis was similar. The adjusted odds of death from sepsis due to a suppressed immune state (odds ratio, 1.21) was significantly lower for these 45 hospitals analyzed as a group relative to that for the patients at the 15 hospitals in the first quartile (P = 0.004 for difference).

"The risk of death from sepsis due to a suppressed immune state was greatest at hospitals with the lowest volume of immunosuppressed patients with sepsis," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »